系统性硬化症相关间质性肺病的病因、危险因素与生物标志物
本文综述系统性硬化症相关间质性肺病(SSc-ILD)的病因、危险因素与生物标志物。约80%的SSc患者发生肺纤维化,25%至30%发展为进展性ILD;风险因素包括高龄、男性、基线HRCT肺受累程度、DlCO降低和FVC降低,抗Scl-70抗体阳性与抗着丝点抗体阴性提示进展风险增加,血清KL-6和CRP升高与严重度及进展相关。
要点
- 约80%的SSc患者发生肺纤维化,25%至30%发展为进展性ILD。
- 高龄、男性、基线HRCT肺受累程度、DlCO和FVC降低是进展风险因素。
- 抗Scl-70抗体阳性、抗着丝点抗体阴性提示进展性ILD可能性增加。
核心结论
- SSc-ILD与IPF有相似之处但存在明确差异,需深入理解其细胞分子发病机制、遗传风险与特征以优化管理。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 约80%的SSc患者发生肺纤维化,25%至30%发展为进展性ILD。
- SSc-ILD进展风险因素包括高龄、男性、基线HRCT肺受累程度、DlCO降低和FVC降低。
- 抗Scl-70抗体阳性与抗着丝点抗体阴性提示进展性ILD可能性增加。
- 血清KL-6和CRP升高与SSc-ILD严重度相关并预测进展,血清CCL18是 promising 的预后指标。
- SSc-ILD组织学常见非特异性间质性肺炎模式,而IPF定义为寻常型间质性肺炎。
关键数值与推荐
- SSc-ILD进展风险因素:高龄、男性、基线HRCT肺受累程度、DlCO降低、FVC降低。
- 抗Scl-70抗体阳性与抗着丝点抗体阴性提示进展性ILD可能性增加。
- 血清KL-6和CRP升高与SSc-ILD严重度相关并预测进展。
临床怎么用
- 对SSc患者应评估基线HRCT肺受累程度、DlCO和FVC以识别进展性ILD高风险者。
- 检测抗Scl-70抗体与抗着丝点抗体有助于判断进展性ILD可能性。
- 血清KL-6、CRP和CCL18可作为SSc-ILD严重度与进展的预后标志物参考。
局限性
- SSc-ILD的关键遗传风险因素尚未确定。
- 血清CCL18作为预后指标仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease. Lung fibrosis occurs in ∼80% of patients with SSc; 25% to 30% develop progressive interstitial lung disease (ILD). The pathogenesis of fibrosis in SSc-associated ILD (SSc-ILD) involves cellular injury, activation/differentiation of mesenchymal cells, and morphological/biological changes in epithelial/endothelial cells. Risk factors for progressive SSc-ILD include older age, male sex, degree of lung involvement on baseline high-resolution computed tomography imaging, reduced DlCO, and reduced FVC. SSc-ILD does not share the genetic risk architecture observed in idiopathic pulmonary fibrosis (IPF), with key risk factors yet to be identified. Presence of anti-Scl-70 antibodies and absence of anti-centromere antibodies indicate increased likelihood of progressive ILD. Elevated levels of serum Krebs von den Lungen-6 and C-reactive protein are both associated with SSc-ILD severity and predict SSc-ILD progression. A promising prognostic indicator is serum chemokine (C-C motif) ligand 18. SSc-ILD shares similarities with IPF, although clear differences exist. Histologically, a nonspecific interstitial pneumonia pattern is commonly observed in SSc-ILD, whereas IPF is defined by usual interstitial pneumonia. The course of SSc-ILD is variable, ranging from minor, stable disease to a progressive course, whereas all patients with IPF experience progression of disease. Although appropriately treated patients with SSc-ILD have better chances of stabilization and survival, a relentlessly progressive course, akin to IPF, is seen in a minority. Better understanding of cellular and molecular pathogenesis, genetic risk, and distinctive features of SSc-ILD and identification of robust prognostic biomarkers are needed for optimal disease management.
引用
- Khanna D, Tashkin DP, Denton CP, et al. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am J Respir Crit Care Med. 2020. PMID: 31841044. doi:10.1164/rccm.201903-0563CI
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。